Fig. 5
Luseogliflozin-mediated improvement in mitochondrial function. (a–d) Western blot analysis and quantification of kidney expression of PGC1α (a, b) and TOM20 (c, d) at 1 week post ischemia/reperfusion (I/R) injury in the following groups: vehicle-treated + sham-operated (n = 6), luseogliflozin-treated + sham-operated (n = 6), vehicle-treated + I/R-injured (n = 6), and luseogliflozin-treated + I/R-injured (n = 6). (e and f) Histological findings and quantification of immunostaining for TOM20 in kidney sections at 1 week post I/R injury in the following groups: vehicle-treated + sham-operated (n = 5), luseogliflozin-treated + sham-operated (n = 5), vehicle-treated + I/R-injured (n = 8), and luseogliflozin-treated + I/R-injured (n = 8); *P < 0.05, **P < 0.01, as determined by one-way analysis of variance. n.s., not significant.
